Edinburgh, Scotland based Synpromics has teamed up with UCL Great Ormond Street Institute of Child Health to develop novel gene therapies for diseases affecting the haematopoietic system.
The collaboration will focus on developing customised synthetic promoters optimised for GE Healthcare’s proprietary biopharmaceutical manufacturing platform.